



## **Patient Safety Analysis**

---

**PDP/MA-PD Contracts  
Overutilization Monitoring System User Guide  
January 2021**

### **Web Portal**

<https://PartD.ProgramInfo.US/PatientSafety>

### **Email**

[PatientSafety@AcumenLLC.com](mailto:PatientSafety@AcumenLLC.com)

### **Phone**

(650) 558-8006

# Table of Contents

1	Introduction .....	1
1.1	Report Access .....	1
1.2	Report and Response Process .....	2
2	Methodology .....	5
2.1	OMS Identification Criteria .....	5
2.1.1	Measurement Period and Data Sources .....	5
2.1.2	Medication and Code Workbook .....	6
2.1.3	Opioid MME Calculation .....	7
2.1.4	Opioid Provider Count Methodology .....	8
2.1.5	Informational Report Metrics .....	9
2.1.6	Update History .....	10
3	OMS Report Structure.....	12
3.1	OMS Reports .....	12
3.1.1	Contract Summary .....	12
3.1.2	Open ORF Cases .....	13
3.1.3	Closed ORF Cases .....	14
3.1.4	SRF Cases .....	15
4	Contract Responses .....	16
4.1	ORF and SRF Information .....	16
4.2	OMS Response Form (ORF) .....	17
4.2.1	Completing the ORF .....	17
4.3	Sponsor Response Form (SRF).....	20
4.3.1	Completing the SRF.....	20
4.4	Suppression Rules.....	23
4.4.1	Additional Sponsor Responses and Suppression Rules .....	25
4.5	Additional Clarifications.....	25
5	Summary and Case Tracking.....	27
5.1	Summary Tracking Page.....	27
5.2	Case Tracking Page .....	27
	Appendix A: Average MME Calculation:.....	28
A.1	Step 1: Calculate Dosage Units per Day and Daily Dose per Claim .....	28
A.1.1	Non-Methadone Claims: .....	28

A.1.2 Methadone Claims:.....	28
A.2 Step 2: Calculate Daily MME.....	29
A.2.1 Daily Non-Methadone MME Calculation: .....	29
A.2.2 Daily Methadone MME Calculation: .....	30
A.2.3 Daily MME Calculation:.....	30
A.3 Step 3: Calculate Average MME .....	31
Appendix B: Pharmacy Grouping Methodology .....	32
Appendix C: Prescriber Grouping Methodology.....	34

## Technical Support

If you need help accessing the Overutilization Monitoring System (OMS) or have questions about the content of the reports, please contact the Acumen, LLC help desk at:

### Email

[PatientSafety@AcumenLLC.com](mailto:PatientSafety@AcumenLLC.com)

### Phone

(650) 558-8006

If you have questions related to the Medicare Part D drug management program requirements, send an email with “DMP” in the subject line to CMS at:

### Email

[PartD\\_OM@cms.hhs.gov](mailto:PartD_OM@cms.hhs.gov)

If you have questions related to MARx drug management program reporting, send an email with “MARx” in the subject line to CMS at:

### Email

[PartD\\_OM@cms.hhs.gov](mailto:PartD_OM@cms.hhs.gov)

# 1 Introduction

---

Section 704 of the Comprehensive Addiction and Recovery Act (CARA) of 2016 included provisions permitting Part D sponsors to establish Drug Management Programs (DMPs) for beneficiaries at-risk for misuse or abuse of frequently abused drugs (FADs). CMS published a final rule (CMS-4182-F) on April 16, 2018 (“final rule”) that established the framework under which Part D plan sponsors may establish a DMP. This rule codified the many aspects of the retrospective Part D Opioid Drug Utilization Review (DUR) Policy and Overutilization Monitoring System (OMS), with adjustments as needed to comply with CARA, by integrating them into the DMP provisions at 42 CFR § 423.153(f).

Since January 2019, sponsors that adopt a DMP must engage in the case management of each Potential At-Risk Beneficiary (PARB) reported through OMS and provide information related to their review within 30 days. In addition, sponsors must also report through OMS any sponsor-identified PARBs, and any newly enrolled PARBs or At-Risk Beneficiaries (ARBs) for which a sponsor received a transaction reply code (TRC) of ‘376’ (New Enrollee CARA Status Notification) from the daily transaction reply report (DTRR).

The following link will take you to additional DMP guidance on the [CMS Part D Overutilization website](#).

Information about navigating the Patient Safety Analysis Web Portal can be found in the Patient Safety Web Portal User Guide, located on the Help Documents page of the Patient Safety Analysis Web Portal.

## 1.1 Report Access

To access the OMS reports (within the Overutilization Monitoring Packages), an authorized user must be added to the Patient Safety Analysis Web Portal. Current authorized users of the Patient Safety Analysis Web Portal with a DMP are automatically granted comparable access to OMS functionality.

All authorized users can navigate the Web Portal and receive email notifications regarding report releases. A user’s access to the OMS is limited to one of two levels, which is determined by the Medicare Compliance Officer (MCO) on Acumen’s User Security Web Portal:

- Summary Report Only: User can access the OMS contract-level rate reports with summary information. Users with Summary Report Only permissions are not able to access beneficiary-level data:
  - The Summary OMS Package (.zip) is titled:  
*ContractID\_Summary\_Overutilization\_Monitoring\_Package\_MMDDYY.zip*
  - The Summary OMS report within the zip file is titled:  
*ContractID\_Summary\_Overutilization\_Monitoring\_Report\_MMDDYY.xlsx*
- Summary and Confidential Beneficiary Reports: User can access confidential beneficiary-level information in the Detail OMS report and the Summary OMS report:

- The Detail OMS Package (.zip) is titled:  
*ContractID\_Detail\_Overutilization\_Monitoring\_Package\_MMDDYY.zip*
- The Detail OMS report within the zip file is titled:  
*ContractID\_Detail\_Overutilization\_Monitoring\_Report\_MMDDYY.xlsx*

A contract's MCO determines the access level of each individual associated with a given contract and can authorize "Summary and Confidential Beneficiary Reports" access for up to five users (including her/himself) per contract. Authorization must be completed through Acumen's User Security Web Portal. The following link will take you to the [Acumen User Security Web Portal](#).

At least one user from each contract must have access to Summary and Confidential Beneficiary Reports in order to view and respond to beneficiary-level reports and forms.

Users should request changes to their permission level through their contract's Medicare Compliance Officer.

Authorized users can download the Overutilization Monitoring Package through the Download Files page. For more information about downloading reports, see the Patient Safety Web Portal User Guide on the Help Documents page of the Patient Safety Analysis Web Portal.

## 1.2 Report and Response Process

The contract-level Overutilization Monitoring Package is provided once each quarter. Sponsors receive an email when the quarterly package is available for download. Each PARB identified by OMS is assigned a case number and is referred to in OMS as either a case or PARB. The case number is specific to the beneficiary and contract. Only contracts with a DMP receive an Overutilization Monitoring Package. Once the package is available, sponsors are to complete the following steps:

1. **Download the Overutilization Monitoring Package(s).** The Overutilization Monitoring Package(s) is available for download on the Download Files page of the Patient Safety Analysis Web Portal on the last business day of the given quarter. The release and submission schedule is available on the Help Documents page of the Patient Safety Web Portal.

- **The Summary OMS Package includes the following files:**

- i. Summary OMS Report (.xlsx):
- ii. Sponsor Response Form (SRF) (.xlsx)
- iii. OMS User Guide (.pdf)
- iv. ORF and SRF Information Workbook (.xlsx)

- **The Detail OMS Package includes the following files:**

- i. Detail OMS Report (.xlsx)

- ii. OMS Response Form (ORF) – if the contract has open cases for review (.xlsx)
  - iii. Sponsor Response Form (SRF) – if the contract has cases for review
  - iv. Verification Response Form (VRF) – if the contract has cases for review
  - v. OMS User Guide (.pdf)
  - vi. ORF and SRF Information Workbook (.xlsx)
2. **Review closed cases (Detail OMS Report).** Cases are closed each quarterly report cycle dependent on sponsors' prior submitted responses or changes to a beneficiary's status.
  3. **Review open cases (Detail OMS Report).** Open cases are reported each quarter and require sponsor responses (see Step 4). Sponsors can use the beneficiary-level information provided in the Detail Overutilization Monitoring Report to assist in performing case management. Unless the sponsor determines that the beneficiary is exempt from the DMP or does not meet the minimum OMS criteria based on plan information, the sponsor must engage in case management through clinical contact with the prescribers to determine if the beneficiary is at-risk and if a coverage limitation(s) is necessary.
  4. **Review SRF cases (Detail OMS Report).** All SRF cases reported by sponsors can be found in the detail report. Sponsors review your SRF cases to verify all cases were successfully submitted and if any updates or deletions are necessary.
  5. **Review VRF cases (VRF).** Sponsor cases with potential data issues identified between the OMS and Medicare Advantage Prescription Drug System (MARx) are reported each quarter, if applicable. Sponsors compare their beneficiaries' MARx records with the last response submitted through OMS to identify discrepancies. If necessary, update the MARx record or submit updated responses using the SRF.
  6. **Complete OMS Response Form (ORF) - if available.** Use the ORF to select the appropriate responses for each case. **Note:** this form is only available to contracts that have open cases in the given quarter. See Section 4.2 for more information about the ORF, including instructions for completing the form.
  7. **Complete Sponsor Response Form (SRF).** Sponsors must use the SRF to report any sponsor-identified PARBs or newly enrolled PARBs or ARBs for which a sponsor received a TRC of '376' (New Enrollee CARA Status Notification) from the DTRR and after requesting the prior contract's case management information. See Section 4.3 for more information about the SRF, including instructions for completing the form.
    - Sponsor-identified cases meet either the minimum OMS criteria or the supplemental OMS criteria. See Section 2.1 for more details regarding the criteria.
    - **Note:** Unlike the ORF, the SRF is made available to all sponsors each quarter. The SRF is expected to be completed by sponsors each quarter. If there are no cases to report in a given quarter, please indicate so in the form.

- 8. Complete Verification Response Form (VRF) - If available.** Sponsors use the VRF to provide an explanation for the potential data issues identified. The VRF will only be included in the Detail OMS Package if CMS has identified records that warrant further explanation. If the VRF is available in the Detail OMS Package, the sponsor will be notified when the OMS reports are released.
- 9. Submit ORF (if available), SRF, and VRF (if available) through the Web Portal.** Once the responses are complete, upload the ORF, SRF, and VRF to the Patient Safety Analysis Web Portal.
- All forms must be submitted as an .xlsx or .zip file via the secure Upload Files feature of the Patient Safety Analysis Web Portal in order to be considered for submission. Forms are not accepted via any other means.
  - Only completed forms are accepted by the Patient Safety Analysis Web Portal. Sponsors can confirm whether a form is completed by checking the 'Overall Form Status' cell at the top of each form (See Table 6), the 'Response Status' column (See Table 8), and the 'Validation Status' or 'Preliminary Validation Status' (See Table 8 and 9) columns for every applicable case.
  - Sponsors must provide responses for open ORF cases and SRF cases within 30 days of the OMS report release date. The submission deadline is provided in the email notification and in the Submission Schedule document on the Help Documents page of the Patient Safety Web Portal. Once the submission deadline passes for that report cycle, the OMS submission window is closed and sponsors who do not submit by the deadline may be subject to compliance action by CMS.
  - Sponsors are expected to submit their VRF within 30 days of the OMS report release date. If a sponsor has questions, send an email to the PartD\_OM@cms.hhs.gov mailbox with the subject 'OMS-MARx DMP Outreach: <Part D contract number>'
  - Past OMS response forms (ORF, SRF, and VRF) are not accepted during a new OMS submission period.
- 10. Confirm upload was successful.** After uploading the forms, view the Process Status on the Upload File History page to confirm the upload was successful. If the upload was successful the Process Status reads "Form(s) processed".
- 11. Confirm case response status.** Use the Case Tracking (Table 12) page to confirm that responses were submitted for each case identified in the ORF. The status of the case must be "Submitted".

Additional information about completing each of these steps is provided in the following sections of this guide.

## 2 Methodology

---

This section describes the current methodology used to identify cases monitored through the OMS.

### 2.1 OMS Identification Criteria

- **Minimum OMS Criteria:** Use of opioids with an average daily morphine milligram equivalent (MME) equal to or exceeding 90 mg for any duration during the most recent 6 months and either: 3 or more opioid prescribers and 3 or more opioid dispensing pharmacies OR 5 or more opioid prescribers, regardless of the number of opioid dispensing pharmacies. These cases are identified through OMS or by sponsors.
- **Supplemental OMS Criteria:** Use of opioids (regardless of average daily MME) during the most recent 6 months with 7 or more opioid prescribers OR 7 or more opioid dispensing pharmacies. These cases are identified by sponsors.

#### 2.1.1 Measurement Period and Data Sources

Measurement Period:	The 6 months prior to the month of a given quarterly report release. This includes Prescription Drug Event (PDE) data from all Part D contracts that a beneficiary is (or was) enrolled with a date of service during the 6 month period.
Data Sources:	<p>Prescription Drug Event (PDE) – used for opioid claims and resident code</p> <p>Common Medicare Environment (CME) – used for enrollment, Low Income Subsidy (LIS) status, and demographic information</p> <p>Medicare Enrollment Database (EDB) – used for hospice enrollment</p> <p>Common Working File (CWF) and Encounter Data System (EDS) – used for cancer and other exemption diagnoses</p> <p>First DataBank (FDB) – used for medication list information</p> <p>Medi-Span – used for medication list information</p>



Centers for Disease Control and Prevention (CDC) Oral MME List<sup>1</sup> (CDC MME List) – identify opioids and their conversion factors (CF) used to calculate the MME of an opioid PDE

Medicare Provider Enrollment, Chain, and Ownership System (PECOS) – used for prescriber information

Health Plan Management System (HPMS) Data – used to identify Part D contracts with a DMP and contract-specific information

Medicare Advantage Prescription Drug (MARx) System – used to identify cases with an active CARA Status (i.e., an open Point of Sale (POS) Edit, Prescriber Limitation, and/or Pharmacy Limitation period)

National Council for Prescription Drug Programs (NCPDP) – used for pharmacy information

## 2.1.2 Medication and Code Workbook

This workbook includes the applicable medication lists and additional codes used to identify exclusions. The medication lists include the characteristics (i.e., product name, strength, strength units, route of administration, dosage form and the opioid CFs) for opioids, benzodiazepines, gabapentin, and pregabalin. The exclusion code list includes International Classification of Diseases -10<sup>th</sup> Revision - Clinical Modification (ICD-10-CM) for cancer diagnoses and palliative care as well as PDE codes used to identify long-term care (LTC) or intermediate care facility (ICF) residents.

The specific National Drug Codes (NDCs) included in the analysis are maintained by Acumen and are created from Medi-Span and First DataBank (FDB) databases. Due to Medi-Span and FDB licensing restrictions, the medication NDCs are not provided. The medication lists are created using the following methodology:

### *Opioid Medication List:*

- All opioid products with the same opioid ingredient, dosage form, and route of administration included on the CDC MME List are identified from the Medi-Span and FDB databases.
- The CDC MME List contains specific exclusions: opium tinctures, cough/cold products, powders, topical, and all opioids administered via intravenous, intrathecal, epidural, or injection (with the exception of buprenorphine subcutaneous prefilled syringe) routes of

---

<sup>1</sup> The following link will take you to the [CDC Analyzing Prescription Data and Morphine Milligram Equivalents \(MME\) site](#), and this additional link will take you to the [Opioid Morphine EQ CF document](#).

administration. These products are excluded from calculation of both the average MME and provider counts.

- Opioid products containing buprenorphine are excluded from the average MME calculations but are included when determining prescriber and pharmacy counts.
- Opioid products containing methadone do not have a static MME CF, but instead utilize a graduated MME CFs based upon the daily MME dose. An overview of the steps used to calculate MME can be reviewed in Section 2.1.3 below.

When the 'quantity dispensed' on PDE claims is counted as 'each', such as transdermal patches and nasal sprays, the MME CF is adjusted to reflect the units and doses billed.

#### *Benzodiazepine Medication List:*

- All benzodiazepine products with the same benzodiazepine ingredient, dosage form, route of administration, and strength included on the Patient Safety Concurrent Use of Opioids and Benzodiazepines Measure NDC list.

#### *Gabapentin and Pregabalin Medication List:*

- All products with 'gabapentin' or 'pregabalin' as an active ingredient and the route of administration is 'oral'.

#### *Exclusion Code List:*

- Cancer ICD-10-CM codes
- Palliative Care ICD-10-CM code
- LTC and ICF PDE resident codes

The OMS medication and code workbook is available on the Help Documents page of the Patient Safety Analysis Web Portal.

## 2.1.3 Opioid MME Calculation

The steps below detail the average MME calculation process.

- To calculate the daily MME for each non-methadone opioid claim, use the following equations:
  - Opioid dosage units per day = (opioid claim quantity) / (opioid claim's days supply)
  - MME daily dose (mg) per claim = (number of opioid dosage units per day) × (opioid strength per unit) × (MME CF<sup>2</sup>)
  - Daily MME = each claim's MME is assigned to each calendar day spanning the date of service (DOS) plus the days supply value minus one day.
- For Methadone claims, use the following equations:

---

<sup>2</sup> Opioid MME CFs are on the Opioid Medication List available on the Help Documents page of the Patient Safety Analysis Web Portal.

- Methadone dosage units per day = (methadone claim quantity) / (methadone claim's days supply)
- Methadone daily dose (mg) per claim = (methadone dosage units per day) × (methadone strength per unit)
- Methadone daily dose per day = each Methadone claim's daily dose is assigned to each calendar day spanning the DOS plus the days supply value minus one day.
- To calculate a beneficiary's MME for each day of the measurement period, use the following equations:
  - Non-methadone total daily MME = for a given day, sum the daily MME across all claims to get the total MME for that day. Repeat for each day of the measurement period.
  - Methadone total daily MME = for a given day, sum the daily dose across all claims to get the total mg dose for that day. Repeat for each day of the measurement period. Then, depending on the total daily dose for each day, multiply by the appropriate graduated methadone MME CF<sup>3</sup>.
  - Total daily MME = (non-methadone total daily MME) + (methadone total daily MME) for each given day of utilization
- The following equations are used to calculate the average MME for each opioid user:
  - Total MME = sum of total daily MME within the measurement period<sup>4</sup>
  - Duration of opioid usage = number of days between first and last day of opioid use within the measurement period (inclusive of first and last days of utilization)
  - Average MME = Total MME / Duration of opioid usage

A detailed example of the MME calculation can be found in Appendix A.

## 2.1.4 Opioid Provider Count Methodology

- Buprenorphine PDE claims contribute towards a beneficiary's opioid prescriber and opioid dispensing pharmacy counts.
- Pharmacy Counts: To count the number of unique opioid dispensing pharmacies, the pharmacy National Provider ID (NPI) is taken from the 'service provider' and 'alternate service provider' IDs on the PDE data. If only the NCPDP pharmacy ID is available, an attempt is made to crosswalk the NCPDP to a NPI. Otherwise, the pharmacy ID found in the 'service provider' field is used. To group pharmacies with multiple locations that share real-time data, the minimum number of groupings identified between the number of unique Federal Tax Identification Numbers (TINs), unique Chain Names, and unique Pharmacy Names<sup>5</sup> among chain pharmacies is identified. This value is added to the

---

<sup>3</sup> Methadone MME CFs are on the Opioid Medication List available on the Help Documents page of the Patient Safety Analysis web portal.

<sup>4</sup> By calculating a daily MME and limiting the total MME to days within the measurement period, any days supply or quantity dispensed beyond the measurement period is excluded.

<sup>5</sup> Pharmacy names are cleaned by removing numbers and extraneous characters (e.g., #) from the Doing Business As (DBA) pharmacy name

unique number of Federal Tax IDs among Franchise and Individual pharmacies. See Appendix B for additional information.

- **Prescriber Counts:** To count the number of unique opioid prescribers, the prescriber NPI is taken from the 'prescriber ID' on the PDE. The PDE NPIs are then matched with the NPIs found in the PECOS database, where relationships between individuals and organizations can be established. Individual prescribers with the same single organizational TIN are grouped and counted as one prescriber. No grouping takes place if a relationship cannot be established or if the PDE does not contain an NPI. See Appendix C for additional information.

Beneficiaries that meet any of the following criteria are not reported:

- Beneficiaries with a LTC or ICF resident code ("03" and "09" respectively) on the last PDE of the 6 month measurement period.
- Beneficiaries with a cancer diagnosis in the CWF or Medicare Advantage encounter data during the 12 months prior to the end of the measurement period.
- Beneficiaries enrolled in hospice, according to EDB, at any point during the 6 month measurement period.
- Beneficiaries with at least 1 inpatient or at least 2 outpatient claims on different dates of service with a Z51.5 ("Encounter for palliative care") diagnosis code in the CWF or Medicare Advantage encounter data during the 6 month measurement period.
- Beneficiaries with a death date in the CME.
- Beneficiaries who are not Part D enrolled as of the last month of the measurement period.
- Beneficiaries with an active CARA Status as of the end of the measurement period i.e., an open period for a POS Edit, Prescriber Limitation, and/or Pharmacy Limitation in MARx for any FAD.
- Beneficiaries suppressed due to an active ORF or SRF exception or sponsor response. See Sections 4.3 and 4.4 for more details regarding ORF and SRF exceptions and sponsor responses that suppress beneficiaries from OMS reporting.

## 2.1.5 Informational Report Metrics

The OMS reports include several metrics for Part D sponsors as supplemental information, including:

- **High Opioid Daily Dose (90 MME) Rate:** Calculated as the total number of opioid utilization days equal to or exceeding 90 MME per 1,000 opioid fill days for all Part D enrolled beneficiaries within the contract during the 6 month measurement period.
- **Total Open ORF Cases with Concurrent Potentiator Drug and Opioid Use:** Concurrent use is defined as at least 1 day of overlapping days supply of both the opioid and potentiator drug claim during the 6 month measurement period. The concurrent opioid-potentiator drug metrics are calculated for the following drugs: benzodiazepine, high dose gabapentin (>2,400 mg), and pregabalin.

## 2.1.6 Update History

January 2021:	<p>RAPS (RxHCC) is no longer used as a data source for identifying exempt beneficiaries.</p> <p>Implemented revised methodology to determine the number of opioid dispensing pharmacies.</p> <p>Verification Response Form (VRF) added to Detail OMS package.</p> <p>Modified SRF PARB reporting language (Section 4.3).</p> <p>Added Section 4.5 Additional Clarification, Appendix B Pharmacy Grouping Methodology, and Appendix C Prescriber Grouping Methodology.</p>
January 2020:	<p>HICN is no longer reported or captured in any reports. Data entry to the HICN field is blocked.</p> <p>Medicare Advantage encounter data added to identify beneficiaries with exempt diagnoses, such as cancer and palliative care.</p> <p>Clarified that the two palliative care outpatient claims are on different dates of service.</p> <p>Change in suppression rule for 'Review in Progress' responses to close cases if the beneficiary has an exemption during the current measurement period.</p> <p>Definition clarifications made to the following response descriptions:</p> <ul style="list-style-type: none"><li>• J. Reason Coverage Limitation Unnecessary – 'Wait and See' (O1)</li><li>• K. Exceptions -- K6, K7 and K9</li><li>• E. Review Status -- 'Review in Progress' (R1) for both the ORF and SRF.</li></ul>
April 2019:	<p><i>Imbedded Validation Check</i> – The ORF and SRF was updated with a 'Validation Status' column to check the validity of responses. All cases must have a 'Complete' Response Status and a 'Valid' Validation Status for the form to be successfully submitted by the 30-day reporting deadline. The validation status for SRF cases is preliminary, pending successful validation of the Medicare Beneficiary Identifier (MBI) fields.</p> <p><i>Validation Reports</i> – The validity of response combinations is now checked within the ORF and SRF instead of through the Validation Reports. SRF cases with invalid MBI fields will be reported to sponsors as 'invalid' in the contract detail reports. Any</p>

'invalid' SRF cases can be deleted and re-submitted through OMS during the next reporting cycle.

*SRF Deletion* – A new response code 'DEL' was added to the 'Method of Identification' element of the SRF. Selecting this response code and 'NA' for all subsequent elements will result in deletion of the SRF case. Sponsors check your contract detail report for confirmation.

*"Update" Response Code Removal* – The 'R3. Update' response code for the 'Review Status' element was removed. 'R2. Review Complete' is used for completed reviews of new cases as well as updated responses to previously reported cases. 'R1. In Progress' can still be used for cases pending completion.

## 3 OMS Report Structure

All Part D sponsors with a Medicare Part D DMP receive a Summary OMS Report with contract-level information regarding the contract's enrollees and their opioid utilization. Sponsors with open cases also receive a Detail OMS Report which contains the same summary overview, along with beneficiary-level information for all open and closed cases identified through OMS (ORF cases).

### 3.1 OMS Reports

This section outlines the levels of analysis included in the Detail OMS Report. Each sub-section contains a description of each metric, any related notes, and a table of key elements that are found in the corresponding worksheets.

#### 3.1.1 Contract Summary

**Worksheet Description:** Presents a summary of open and closed cases reported through OMS at the contract-level. The Contract Summary worksheet provides two tables: a summary of the sponsor's current enrollees and open cases, as well as a historical (overall) summary of ORF and SRF cases reported. These summary metrics are broken out at the following beneficiary group levels: All Enrollees, Non-LIS Beneficiaries, and LIS Beneficiaries.

**Key Elements:**

Table 1: Current Summary Key Elements

Key Element	Definition
<b>Total Part D Enrollees</b>	Total number of Part D beneficiaries enrolled in contract during the period measured.
<b>Total Opioid Utilizers</b>	Total number of beneficiaries with at least one prescription fill for an opioid.
<b>% of Enrollees who are Opioid Utilizers</b>	Calculated as Total Opioid Utilizers / Total Part D Enrollees
<b>Total Open ORF Cases</b>	Total number of beneficiaries identified as a case (PARBs) by meeting the minimum OMS criteria. This number may include beneficiaries who were identified as a case in a previous OMS report and do not meet the exception criteria.
<b>% of Opioid Users that are Open ORF Cases</b>	Calculated as Total Open ORF Cases / Total Opioid Utilizers
<b>Total Open ORF Cases with Concurrent Benzodiazepine and Opioid Use</b>	Total number of open ORF cases where the beneficiary has at least one day of concurrent benzodiazepine and opioid use.
<b>Total Open ORF Cases with Concurrent High Dose Gabapentin (&gt;2400 mg) and Opioid Use</b>	Total number of open ORF cases where the beneficiary has at least one day of concurrent high dose gabapentin (> 2,400 mg) and opioid use.

Key Element	Definition
<b>Total Open ORF Cases with Concurrent Pregabalin and Opioid Use</b>	Total number of open ORF cases where the beneficiary has at least one day of concurrent pregabalin and opioid use.
<b>High Opioid Daily Dose (90 MME) Rate</b>	Total number of opioid utilization days with at least a 90 MME daily dose per 1,000 opioid utilization days for all opioid utilizers.
<b>Total Open SRF Cases</b>	Total number of beneficiaries identified as open SRF cases.

Table 2: Overall Summary Key Elements

Key Element	Definition
<b>Open ORF Cases - Response Expected</b>	Total number of beneficiaries identified as a case (PARBs) by meeting the minimum OMS criteria. This number may include beneficiaries who were identified as a case in a previous OMS report and do not meet the exception criteria.
<b>Total ORF Cases Reported Since Mon-YYYY</b>	Total number of beneficiaries ever identified as a case (PARB) according to the minimum OMS criteria. This number includes all open and closed cases.
<b>Total Closed ORF Cases Since Mon-YYYY</b>	Total number of beneficiaries previously identified as a case (PARB) by meeting the minimum OMS criteria, but currently closed.
<b>Total SRF Cases since Mon-YYYY</b>	Total number of beneficiaries ever identified by sponsors via SRF. This number may include closed, as well as open SRF cases.

### 3.1.2 Open ORF Cases

Worksheet Description: Presents a list of all currently open ORF cases requiring a response along with opioid utilization information for each case.

Key Elements:

Table 3: Open ORF Cases Key Elements

Key Element	Definition
<b>Case Number</b>	The unique identifier assigned to a beneficiary for the given contract.
<b>HICN</b>	The beneficiary's Health Insurance Claim Number. No longer reported or collected as of January 2020.
<b>MBI</b>	The beneficiary's Medicare Beneficiary Identifier.
<b>DOB</b>	The beneficiary's date of birth.
<b>PBP ID</b>	The beneficiary's plan benefit package (PBP) ID number.
<b>LIS Status</b>	The beneficiary's low-income subsidy (LIS) status. "Y" indicates the beneficiary ever had LIS status and "N" indicates the beneficiary never had LIS status during their Part D enrollment within the measurement period.
<b>Date First Reported</b>	Indicates the date that the beneficiary was first reported to the sponsor.
<b>Measurement Period</b>	Indicates the period in which the beneficiary was identified as a case (PARB).
<b>Prior Contracts Contributing to Utilization</b>	List of beneficiary's prior contracts from PDE data that contributed to the beneficiary's utilization. If this field is empty, all claims contributing to the beneficiary's utilization were filled through the contract on the report.



Key Element	Definition
<b>Duration of Opioid Use</b>	Number of days between first and last opioid use during the measurement period (calculated as days from the first opioid fill date of service to the last day of opioid use during the measurement period)
<b>Total MME</b>	Total MME utilized by the beneficiary during the measurement period.
<b>Average Daily MME</b>	The average daily MME, calculated as 'Total MME' divided by 'Duration of Opioid Use'.
<b>Concurrent Benzodiazepine and Opioid Use</b>	Concurrent usage of a benzodiazepine and an opioid for at least one day. (N = No and Y = Yes)
<b>Concurrent High Dose Gabapentin (&gt;2400 mg) and Opioid Use</b>	Concurrent usage of high dose gabapentin (> 2,400 mg) and an opioid for at least one day. (N = No and Y = Yes)
<b>Concurrent Pregabalin and Opioid Use</b>	Concurrent usage of pregabalin and an opioid for at least one day. (N = No and Y = Yes)
<b>Number of Pharmacies Contributing to Opioid Claims</b>	Total number of distinct pharmacies that filled opioid claims.
<b>Number of Prescribers Contributing to Opioid Claims</b>	Total number of distinct prescribers with different Tax IDs that were attributed to opioid prescriptions.
<b>Prior Submitted Review Status</b>	The last review status reported by the contract for a case (PARB) reported to the contract through OMS. See Table 8. Element E. Review Status Codes (R1-R2). New cases have a review status "NA".

### 3.1.3 Closed ORF Cases

Worksheet Description: Presents a list of all previously identified but currently closed cases along with the reason for the closed status.

Key Elements:

Table 4: Closed Cases Key Elements

Key Element	Definition
<b>Case Number</b>	The unique identifier assigned to a beneficiary for the given contract.
<b>HICN</b>	The beneficiary's Health Insurance Claim Number. No longer reported or collected as of January 2020.
<b>MBI</b>	The beneficiary's Medicare Beneficiary Identifier.
<b>DOB</b>	The beneficiary's date of birth.
<b>PBP ID</b>	The beneficiary's plan benefit package (PBP) ID number.
<b>LIS Status</b>	The beneficiary's low-income subsidy (LIS) status. "Y" indicates the beneficiary ever had LIS status and "N" indicates the beneficiary never had LIS status during their Part D enrollment within the measurement period.
<b>Date Closed</b>	Indicates the report date that the case was closed.
<b>Current Exclusion: Death or Lacks Part D Eligibility</b>	Case closed due to death, Part D disenrollment, or disenrollment from contract associated with case number. "Y" indicates the case was closed for this reason and "N" indicates that it was not applicable.

Key Element	Definition
<b>Current Exemption: Cancer, Hospice, Palliative Care, or Facility</b>	Case closed due to cancer diagnosis, hospice enrollment, palliative care diagnosis, or residence in an exempt facility. “Y” indicates the case was closed for this reason and “N” indicates not applicable.
<b>Does Not Meet Minimum OMS Criteria</b>	Case closed as beneficiary does not meet minimum OMS criteria at the time of the report. “Y” indicates the case was closed for this reason and “N” indicates not applicable.
<b>Suppressed from OMS due to Sponsor Prior Response</b>	Case closed due to sponsor provided response in the ORF. “Y” indicates the case was closed for this reason and “N” indicates not applicable.
<b>Active CARA Status in MARx</b>	Case closed due to active CARA Status in MARx (i.e., FAD notification or implementation of a coverage limitation). “Y” indicates the case was closed for this reason and “N” indicates that it was not applicable.
<b>Prior Submitted Review Status</b>	The last review status reported by the contract for a case previously reported to the contract through OMS. See Table 8. Element E. Review Status Codes (R1-R2).

Note: Cases with a ‘Review Complete’ status are closed when the beneficiary’s drug utilization no longer meets the minimum OMS criteria, regardless if the Part D contract previously reported that the beneficiary had an OMS exception (Table 10). Similarly, cases with a ‘Review in Progress’ status who do not meet the minimum OMS criteria during the current measurement period are closed and not re-reported to the sponsor. However, if the sponsor subsequently sends an initial notice to the beneficiary identifying them as a PARB, the sponsor must submit the information in MARx within 7 days and an updated response through OMS within 30 days of the most recent OMS report release. See section 4.5 for further information on updating cases.

### 3.1.4 SRF Cases

Worksheet Description: Presents a list of all submitted SRF cases.

Key Elements:

Table 5: SRF Cases Key Elements

Key Element	Definition
<b>HICN</b>	The beneficiary’s Health Insurance Claim Number. No longer reported or collected as of January 2020.
<b>MBI</b>	The beneficiary’s Medicare Beneficiary Identifier.
<b>DOB</b>	The beneficiary’s date of birth.
<b>PBP ID</b>	The beneficiary’s plan benefit package (PBP) ID number.
<b>LIS Status</b>	The beneficiary’s low-income subsidy (LIS) status. “Y” indicates the beneficiary ever had LIS status and “N” indicates the beneficiary never had LIS status during their Part D enrollment within the measurement period.
<b>Submission Date</b>	The date of the submission period deadline when the case was submitted.
<b>Validation Status</b>	The case’s validation status. “Y” indicates that the MBI is valid and “N” indicates the MBI is invalid. Invalid cases are not used.

## 4 Contract Responses

Sponsors must respond to each case identified by OMS using the OMS Response Form (ORF) included in the downloadable Detail OMS Package. Additionally, sponsors must report internally identified cases using the Sponsor Response Form (SRF). This section describes the process and instructions for completing and submitting both the ORF and the SRF. Table 6 provides an overview of the key status definitions within the ORF and SRF.

Table 6: ORF and SRF Status Definitions

Key Element	Definition
<b>Overall Form Status</b>	<b>Incomplete</b> = One or more cases have a missing response code, one or more cases have invalid response combinations, or one or more of the Responder Identification fields are blank. <b>Note:</b> All acceptable response codes are provided in the drop-down menus within the response forms. Incomplete forms will not be accepted by the Web Portal.  <b>Complete</b> = All cases have a 'Complete' Review Status and 'Valid' Validation (for ORFs) or Preliminary Validation (for SRFs) Status.
<b># of Cases</b>	Number of cases requiring a response in the given form.
<b># of Valid Cases</b>	Number of cases with a 'Complete' Review Status and a 'Valid' Validation (for ORFs) or Preliminary Validation (for SRFs) Status in the given form. <b>Note:</b> For the SRF, submission of invalid MBIs lead to individual cases being deemed 'Invalid'.

Additional information, including flowcharts that provide a visual illustration for completing the response form(s), response form layouts with descriptions and formats for each data element, and full descriptions of the response codes, can be found in the ORF and SRF Information workbook included in the Overutilization Monitoring packages, and on the Help Documents page of the Patient Safety Web Portal, and on CMS.gov. The following link will take you to the [CMS Part D Overutilization website](#) that contains this workbook.

### 4.1 ORF and SRF Information

Before responding to each case identified by OMS in the ORF or internally identified cases in the SRF, it is recommended that sponsors review the 'ORF and SRF Information Workbook'. This workbook helps sponsors ensure that the ORF and SRF forms are populated completely with valid response combinations for each case. This workbook contains the following information:

Table 7. ORF and SRF Information Workbook Layout

Workbook Tab	Description
<b>ORF Flowchart</b>	This tab depicts the logic tree for the ORF reporting process and all response codes.
<b>SRF Flowchart</b>	This tab depicts the logic tree for the SRF reporting process and all response codes.
<b>Response File Layouts</b>	This tab lists the detailed descriptions of each data element, as well as each data element's format and possible values.
<b>Response Codes</b>	This tab lists detailed descriptions of all ORF and SRF response codes.

Workbook Tab	Description
ORF Valid Cases	This tab lists all expected valid response code combinations for ORF cases.
SRF Valid Cases	This tab lists all expected valid response code combinations for a SRF cases.

Following the flowcharts, response file layouts, response codes descriptions, and the list of case valid response code combinations as described in the ORF and SRF Information workbook ensure that your submitted responses are processed and receive a Validation (for ORFs) or Preliminary Validation (for SRFs) Status of 'Valid'.

## 4.2 OMS Response Form (ORF)

Sponsors with a DMP and open ORF cases receive an ORF within the Detail OMS Package that is prepopulated with the case number, MBI, and DOB for each case. If there are no open cases, an ORF is not provided.

Sponsors must use the current ORF to respond to all open cases. That is, respond to new cases or update pending cases (i.e., where previous response was 'Review in Progress' and no exemptions are identified). **Note:** If the ORF is submitted multiple times during the 30 day submission period, only the responses in the most recent ORF are used.

### 4.2.1 Completing the ORF

Table 8 and the accompanying notes provide an overview of the response codes that must be selected in the ORF for a given case for elements E through K. **If a response code is not applicable to a particular aspect of a given case, 'NA' must be selected in the field to have a valid response. Only one 'Final Response' code, as indicated in the Response Description column below, can be selected for each case number, except for element K. Multiple 'Y' or 'N' responses are acceptable for 'K.1-9 Exceptions' (see Table 10). Use the 'Response Status' field to check the completeness of a case's responses and the 'Validation Status' field to check the validity of a case's response combination.**

Table 8: ORF Response Codes

Table Element. Response Category	Response Code	Response Name	Response Description
A. Case Number	–	–	CMS-assigned case number at the beneficiary-contract level.
B. HICN	–	–	Health Insurance Claim Number. No longer reported or collected as of January 2020.
C. MBI	–	–	Medicare Beneficiary Identifier
D. DOB	–	–	Date of Birth

Table Element. Response Category	Response Code	Response Name	Response Description
<b>E. Review Status</b>	<b>R1</b>	Review in Progress	Sponsor's review is pending and no clinical contact (either written report or further attempted contact) was made with prescribers. For example, the sponsor's review of the case has not started, or the sponsor is still reviewing internal data to determine if the beneficiary has a DMP exemption, does not meet the minimum OMS criteria in a 6 month measurement period, or has another exception. All subsequent element responses are NA. <b>Final Response*</b>
	<b>R2</b>	Review Complete	Sponsor's review of a newly identified or an in-progress case from a prior report is complete. <b>Proceed to 'F. Clinical Contact Status'</b>
<b>F. Clinical Contact Status</b>	<b>C1</b>	Clinical Contact - Only Written Report Sent to Prescriber(s)	Only written information and inquiry letter sent to prescriber(s). <b>Proceed to 'G. Prescriber Verification'</b>
	<b>C2</b>	Further Clinical Contact Attempted	Further clinical contact attempted with prescribers (in addition to required written information), such as a phone call. <b>Proceed to 'G. Prescriber Verification'</b>
	<b>C3</b>	Other - No Clinical Contact Due to Exception(s)	No clinical contact is made with prescribers because the sponsor identified from internal data that the beneficiary has an exception(s). <b>Proceed to 'K. Exceptions'</b>
	<b>NA</b>	Not Applicable	If 'E. Review Status' = 'R1'
<b>G. Prescriber Verification</b>	<b>Y</b>	Yes	Prescriber(s) verified that the beneficiary is at-risk. <b>Proceed to 'H. Coverage Limitation Necessary'</b>
	<b>N</b>	No	Prescriber(s) verified that the beneficiary is NOT at-risk. <b>Proceed to 'H. Coverage Limitation Necessary'</b>
	<b>NR</b>	No Response	No response from prescriber(s). <b>Proceed to 'H. Coverage Limitation Necessary'</b>
	<b>NA</b>	Not Applicable	If 'F. Clinical Contact Status' = 'C3' or 'NA'
<b>H. Coverage Limitation Necessary</b>	<b>Y</b>	Yes	Sponsor decided that a coverage limitation(s) is necessary. <b>Proceed to 'I. Prescriber Agreed to Coverage Limitation'</b>
	<b>N</b>	No	Sponsor does not intend to implement a coverage limitation(s). <b>Proceed to 'J. Reason Coverage Limitation Unnecessary'</b>
	<b>NA</b>	Not Applicable	If G. Prescriber Verification = 'NA'
<b>I. Prescriber Agreed to Coverage Limitation</b>	<b>Y</b>	Yes	Prescriber agreed that a coverage limitation(s) was necessary. <b>Final Response*</b>
	<b>N</b>	No	Prescriber did not agree that a coverage limitation was necessary. <b>Final Response*</b>
	<b>NR</b>	No Response	No response from prescriber(s). <b>Final Response*</b>
	<b>NA</b>	Not Applicable	'H. Coverage Limitation Necessary' = 'N' or 'NA'

Table Element. Response Category	Response Code	Response Name	Response Description
<b>J. Reason Coverage Limitation Unnecessary</b>	<b>O1</b>	Wait and See	After written information is sent to the prescriber, sponsor is taking a “wait and see” approach to monitor the beneficiary’s FAD use to see if the prescribers adjust their care of their patient or respond to the sent information, such that the beneficiary no longer meets the OMS criteria during a subsequent 6 month period. <b>Final Response*</b>
	<b>O2</b>	Prescriber(s) Agreed During Clinical Contact to Manage/Coordinate Care	Coverage limitation is not necessary; the prescriber will manage/coordinate the beneficiary’s FAD use. <b>Final Response*</b>
	<b>O3</b>	Prescriber(s) Attested During Clinical Contact that the Medication Regimen is Appropriate	Coverage limitation is not necessary, prescriber verified that the <b>total</b> FAD regimen is medically necessary. <b>Final Response*</b>
	<b>O4</b>	Clinical Contact Determined has a Beneficiary Exception(s)	During case management it was determined the beneficiary has an exception. <b>Proceed to K. ‘Exceptions’</b>
	<b>NA</b>	Not applicable	If ‘H. Coverage Limitation Necessary’ = ‘Y’ or ‘NA’
<b>K. 1-9 Exceptions (see Table 10)</b>	<b>Y</b>	Yes	The beneficiary has a DMP exemption, does not meet the OMS criteria in a 6 month measurement period, or has another exception. <b>Final Response(s)**</b>
	<b>N</b>	No	The beneficiary does not have the exception. <b>Final Response(s)**</b>
	<b>NA</b>	Not Applicable	If ‘J. Reason Coverage Limitation Unnecessary’ is NOT ‘O4’ AND ‘F. Clinical Contact Status’ is NOT ‘C3’
<b>Response Status</b>	<b>Complete</b>	Checks that acceptable response codes are populated for each element. Only the responses in the drop-down box are accepted for each element. A correctly populated row has a ‘Complete’ status while a row with any missing or unacceptable responses has an ‘Incomplete Response’ status.	
<b>Validation Status</b>	<b>Valid</b>	If the ‘Response Status’ is complete, a Validation Status of ‘Valid’ confirms that that the response combination in the row meets the current validation logic.	

\*Only one ‘Final Response’ code, as indicated in the Response Description column, can be selected for each case number except for element K.

\*\*Multiple ‘Y’ or ‘N’ responses are acceptable for ‘K. 1-9 Exceptions’ (see Table 10).

Notes:

- If the Overall Form Status is “Incomplete” the form is not processed or recorded.

- If multiple ORFs are received for a given case number, the most recent complete response received by the close of the submission period is used. An incomplete response uploaded after a complete response will not replace the latest complete response for that case.
- If an ORF from a previous reporting cycle is submitted during a current cycle, responses for the cases are not processed.

## 4.3 Sponsor Response Form (SRF)

Sponsors must also report to CMS PARBs identified by the sponsor who met either the minimum OMS criteria or the supplemental OMS criteria, and the sponsor determined that a coverage limitation was necessary (meaning they did or will send the initial notice) or not necessary through the case management process. Thus, the reported review status is complete. Sponsors must also report newly enrolled beneficiaries for which a sponsor received a TRC of '376' (New Enrollee CARA Status Notification) from the daily transaction reply report (DTRR). Sponsors may report these cases as in progress or complete depending on when they received the enrollment request and when the OMS report is due. In addition, if the sponsor determines that a currently closed ORF case's status necessitates updating in OMS (e.g., a coverage limitation is deemed necessary), the sponsor should report the beneficiary and responses in the SRF using the MBI.

**Note:** The SRF is independent of the ORF, and the two forms cannot be used interchangeably. The SRF that is provided in a given quarter must be used in that quarter (i.e., previous versions of the SRF from different quarters are not processed by the Web Portal). If the SRF is submitted multiple times during a given quarter, only the most recent responses are used.

### 4.3.1 Completing the SRF

This section details the data elements and response codes that are specific to the SRF. All other data elements and response codes from the ORF section apply to SRF in the same manner.

First, after completing the responder information portion of the form, answer the question in Cell B13: 'Has the sponsor internally identified any cases?'

- **If 'N' (No)**, then leave the remainder of the SRF blank, save the form to your desktop, and upload the form to the Patient Safety Analysis Web Portal using the Upload Files page
- **If 'Y' (Yes)**, then populate the form with the sponsor identified cases using the remainder of this section as a guide

For each SRF case, the MBI and the DOB fields must be populated by the sponsor. If the DOB is not available to the sponsor, please populate the element with "NA".

The SRF includes all the elements in the ORF (see Table 8) plus Elements **S. Method of Identification** and **T. Prior Sponsor Beneficiary CARA Status**. Some responses in the SRF are not valid in the ORF.

Cases with a Method of Identification response code of 'DEL' that do not match a previously submitted case are considered invalid and are excluded from OMS reports.

Key differences in elements are noted below:

Table 9: SRF Response Codes

Table Element / Response Category	Response Code	Response Name	Response Description
<b>S. Method of Identification</b>	<b>M1</b>	Met Minimum OMS Criteria	The beneficiary met the minimum OMS criteria. <b>Proceed to 'E. Review Status'.</b>
	<b>M2</b>	Met Supplemental OMS Criteria	The beneficiary met the supplemental OMS criteria. <b>Proceed to 'E. Review Status'.</b>
	<b>M3</b>	Notice Upon Enrollment – Active CARA Status	The sponsor received an active CARA Status notification for the beneficiary. <b>Proceed to 'T. Prior Sponsor Beneficiary CARA Status'.</b>
	<b>DEL</b>	Delete SRF Case	The beneficiary is no longer identified as an SRF case and is deleted. <b>Final Response*</b>
<b>T. Prior Sponsor Beneficiary CARA Status</b> <i>Only applies if the response to S. = M3</i>	<b>P1</b>	At-Risk Beneficiary with a Coverage Limitation Implemented	Indicates that successful communication was established with the prior Part D sponsor and the beneficiary had an implemented coverage limitation(s) under the prior contract. <b>Proceed to 'E. Review Status'.</b>
	<b>P2</b>	No Response from Prior Plan	Indicates that attempted contact with the prior Part D sponsor was unsuccessful. <b>Proceed to 'E. Review Status'.</b>
	<b>P3</b>	Potential At-Risk Beneficiary with No Coverage Limitation Implemented	Indicates successful communication was established with the prior Part D sponsor and the beneficiary coverage limitation(s) were pending. <b>Proceed to 'E. Review Status'.</b>
	<b>NA</b>	Not Applicable	If 'S. Method of Identification' = 'M1' or 'M2'.



Table Element / Response Category	Response Code	Response Name	Response Description
<b>E. Review Status</b>	<b>R1</b>	Review in Progress	Only applicable to M3 Notice Upon Enrollment – Active CARA Status. Sponsor's review is pending and no clinical contact (either written report or further attempted contact) was made with prescribers. For example, the current contract is in the process of contacting the prior contract, or gathering or reviewing the information from the prior contract. <b>Final Response*</b>
	<b>R2</b>	Review Complete	Sponsor's review of a case is complete. <b>Proceed to 'F. Clinical Contact Status'</b>
	<b>NA</b>	Not Applicable	If 'S. Method of Identification' = 'DEL'
<b>F. Clinical Contact Status</b>	<b>C1</b>	Clinical Contact – Only Written Report Sent to Prescriber(s)	Only written information and an inquiry letter sent to the prescriber(s). <b>Proceed to 'G. Prescriber Verification'.</b>
	<b>C2</b>	Further Clinical Contact Attempted	Further clinical contact attempted with prescribers (in addition to required written information), such as phone call. <b>Proceed to 'G. Prescriber Verification'.</b>
	<b>C3</b>	Other – No Clinical Contact due to Exception(s)	No clinical contact is made with prescribers because the sponsor identified from internal data that the beneficiary has an exception(s). <b>Proceed to 'K. Exceptions'.</b>
	<b>C4<sup>6</sup></b>	Exempt from Case Management	Sponsor obtained case management information from the previous sponsor and such information is clinically adequate and up to date. <b>Proceed to 'H. Coverage Limitation Necessary'.</b>
	<b>NA</b>	Not Applicable	If 'E. Review Status' = 'R1'
<b>G. Prescriber Verification</b>	<b>Y</b>	Yes	If 'F. Clinical Contact Status' = 'C1' or 'C2' AND Prescriber(s) verified that the beneficiary is at-risk. <b>Proceed to 'H. Coverage Limitation Necessary'.</b>

---

<sup>6</sup> Note: A response of 'F. Clinical Contact Status' = 'C4' (Exempt from Case Management) can only be selected if 'S. Method of Identification' = 'M3' (Notice Upon Enrollment - Active CARA Status).

Table Element / Response Category	Response Code	Response Name	Response Description
<b>G. Prescriber Verification (continued)</b>	<b>N</b>	No	If 'F. Clinical Contact Status' = 'C1' or 'C2' AND Prescriber(s) verified that the beneficiary is NOT at-risk. <b>Proceed to 'H. Coverage Limitation Necessary'</b>
	<b>NR</b>	No Response	If 'F. Clinical Contact Status' = 'C1' or 'C2' AND No response from prescriber(s). <b>Proceed to 'H. Coverage Limitation Necessary'</b> .
	<b>NA</b>	Not Applicable	If 'F. Clinical Contact Status' = 'C3', 'C4', or 'NA'
<b>Complete remaining elements in Table 8 and Table 10.</b>			
<b>Response Status</b>	<b>Complete</b>	Checks that acceptable response codes are populated for each element. Only the responses in the drop-down box are accepted for each element. A correctly populated row has a 'Complete' status while a row with any missing or unacceptable responses has an 'Incomplete Response' status.	
<b>Preliminary Validation Status</b>	<b>Valid</b>	If the 'Response Status' is complete, a Validation Status of 'Valid' confirms that the response combination in the row meets the current validation logic. Note if the MBI element is populated incorrectly, the case is deemed invalid.	

Once the form is complete, save the form to your desktop, and upload the file to the Patient Safety Analysis Web Portal using the Upload Files page. For detailed information about the using the Upload Files and Upload File History pages, see the Patient Safety Web Portal User Guide on the Help Documents page of the Patient Safety Analysis Web Portal.

## 4.4 Suppression Rules

The following is the list of ORF and SRF exceptions that a sponsor may identify for a particular case based on internal data or through case management. The exceptions generally include three types: DMP required exemptions, administrative exclusions, and other exceptions because the beneficiary's opioid use does not meet the minimum OMS criteria in a 6 month measurement period. Select "Y" for all the exceptions that apply to the case. The list also includes the maximum time that a case is suppressed from OMS reporting while the beneficiary is enrolled in the same contract.

If the sponsor's response to '**F. Clinical Contact Status**' = '**C3**' or '**J. Reason Coverage Limitation Unnecessary**' = '**O4**', at least one '**K. Exception**' elements 1-9 is populated with 'Y'. Otherwise, sponsors populate the '**K. Exceptions**' elements with 'NA'. In addition, if the supplemental OMS criteria was used by the sponsor to identify a case, a response of 'NA' would be appropriate for K8 and K9 since MME is not applicable.

Table 10. List of OMS Report Exceptions and Suppression Rules

Element	Exception	Description	Suppression Rule
K1.	Exemption: Resident of an Exempt Facility	Beneficiary is a resident of a long-term care facility, of a facility described in section 1905(d) of the Act, or of another facility for which frequently abused drugs are dispensed for residents through a contract with a single pharmacy.	Exclude from OMS reporting if last PDE Patient Resident Code is 3 or 9.
K2.	Exemption: Active Cancer-Related Pain	Beneficiary is being treated for active cancer-related pain.	Y=Suppressed up to 1 year, date of death (DOD) or disenrollment.
K3.	Exemption: Hospice, Palliative or End-of-Life Care	Beneficiary has elected to receive hospice care or is receiving palliative or end-of-life care.	Y=Suppressed up to 1 year, DOD or disenrollment.
K4.	Administrative Exclusion: Deceased	Beneficiary is deceased.	Exclude from OMS reporting based on CME.
K5.	Administrative Exclusion: Disenrolled or Lacks Part D Eligibility	Beneficiary not enrolled in a Part D plan or lacks Part D eligibility.	Exclude from OMS reporting based on CME.
K6.	OMS Criteria Not Met: Prescriber Count	OMS criteria not met because the number of prescribers is below the prescriber count. For example, sponsor identified that prescribers within the same group practice are treated as one prescriber or in a recent 6 month measurement period the number of prescribers is below the count.	Y=Suppressed up to 1 year, DOD or disenrollment.
K7.	OMS Criteria Not Met: Pharmacy Count	OMS criteria not met because the number of pharmacies is below the pharmacy count. For example, sponsor identified that pharmacies with multiple locations that share real-time electronic data are treated as one pharmacy or in a recent 6 month measurement period the number of dispensing pharmacies is below the count.	Y=Suppressed up to 1 year, DOD or disenrollment.
K8.	OMS Criteria Not Met: MME Approved Due to Favorable Coverage Determination or Appeal	OMS criteria not met because of a favorable coverage determination or appeal.	Y=Suppressed up to 1 year, DOD or disenrollment.
K9.	OMS Criteria Not Met: MME for Other Reasons	OMS criteria not met because the MME is below the threshold. For example, sponsor identified that the MME threshold is not met due to appropriate prescription fill overlap, data entry error, or an acute/temporary short-term high use, or based on changes in utilization in a recent 6 month measurement period.	None

## 4.4.1 Additional Sponsor Responses and Suppression Rules

Other sponsor responses that result in the case being suppressed from OMS reporting include the following:

Table 11. Additional Sponsor Responses and Suppression Rules

Element	Final Response	Description	Suppression Rule
<b>H. Coverage Limitation Necessary</b>	Yes	Sponsor intends to implement a coverage limitation(s).	The beneficiary has an active CARA Status (i.e., coverage limitation notification or implementation period for a FAD) in MARx as of the last day in the measurement period.
<b>J. Reason Coverage Limitation Unnecessary</b>	O2	Prescriber(s) agreed during clinical contact to manage/coordinate care.	Y=Suppressed up to 1 year, DOD or disenrollment.
	O3	Prescriber(s) attested during clinical contact that the medication regimen is appropriate.	Y=Suppressed up to 1 year, DOD or disenrollment.
	O4 and at least one K.1-9 response is Yes	Clinical contact determined beneficiary exception: exemption, OMS criteria not met, or administrative exclusion identified.	Y=Suppression rules apply as described in Table 10.

## 4.5 Additional Clarifications

Based on monitoring OMS and MARx reporting, here are additional clarifications to sponsor's reporting via the OMS:

### 1. OMS Responses and MARx Coverage Limitations

If the sponsor submits a response for a case (PARB) that indicates either a 'No' or 'N/A' for 'H. Coverage Limitation Necessary' (e.g., case may be complete at that time, or may be 'Review in Progress' or 'Wait and See'), and the sponsor later determines that a coverage limitation is necessary, the sponsor sends the beneficiary the initial notice and must submit the information to MARx within 7 days of the initial notice date. The sponsor should then also update OMS with the new response within 30 days of the most recent OMS report release date (i.e. the OMS report submission due date).

### 2. Medication-Assisted Treatment (MAT) Prescribers

Buprenorphine products are not used to determine the beneficiary's average daily MME. However, prescription opioids including all formulations of buprenorphine for pain and MAT, are used to determine opioid prescribers and opioid dispensing pharmacies under the

minimum OMS criteria. Therefore, sponsors should not exclude the MAT prescriber(s) or pharmacy(ies) when determining if the beneficiary's opioid use meets the OMS criteria.

Case management under DMPs provides an opportunity to improve care coordination and treatment for the beneficiary. CMS recommends that Part D sponsors consider if the beneficiary was switched to MAT but is still taking non-MAT opioids concurrently. If an MAT opioid prescriber is a new prescriber, sponsors may want to consider reporting 'Review in progress' while working to verify that non-MAT opioids are not continued, or while performing case management outreach to non-MAT prescribers to coordinate care. If a coverage limitation is determined NOT necessary, submit the appropriate OMS response and reason. Furthermore, if there is no prescriber response after clinical contact, the sponsor may want to consider a 'Wait and See' approach to monitor if the MAT treatment continues with or without concurrent non-MAT opioid use.

### 3. Acute Short-Course of Opioids

As reiterated above, all opioids should be included when determining the number of opioid prescribers or pharmacies. If the MME remains *above* the OMS criteria threshold after accounting for a short-course of opioids, and the beneficiary meets the pharmacy and prescriber counts, the beneficiary meets the OMS criteria and the sponsor must review the case unless the beneficiary has a DMP exemption. Sponsors should not report OMS Criteria Not Met: MME for Other Reasons' (See Table 10. K9) exception. Inappropriate responses would result in the beneficiary being suppressed from the OMS for 12 months despite the OMS criteria being met.

If the MME is *below* the MME threshold after accounting for a short-course of opioids, the beneficiary does not meet the OMS criteria and the sponsor should report 'OMS Criteria Not Met: MME for Other Reasons'.

### 4. Failure to Submit ORF and SRF by Deadline

Contracts that fail to timely submit their ORF are out of compliance with the data disclosure requirements found at 42 CFR § 423.153(f)(15). Once the OMS report submission deadline has passed, the OMS submission window is closed for that OMS quarterly cycle and the associated response forms are no longer accepted or valid. Open cases associated with the prior missing ORF will be re-reported to the contract in the next quarterly OMS report's ORF. If an ORF case(s) with a missing response is not reported in the next quarterly OMS report's ORF and the sponsor wants the response(s) recorded in OMS, the sponsor should submit the case(s) using their SRF.

If the sponsor also failed to submit their SRF by the OMS submission deadline, it must submit sponsor identified PARBs and cases for which a sponsor received a transaction reply code of TRC 376 from the DTRR using the current SRF. However, if the missing SRF case was identified by the sponsor using the minimum OMS criteria and is identified in the next quarterly OMS report's ORF, the sponsor must provide a response in the ORF and should not report the case in the SRF.

## 5 Summary and Case Tracking

In addition to downloading reports and uploading forms, sponsors can use the OMS to track ORF cases over time. The following sections provide an overview of the Summary Tracking and Case Tracking pages, and describe how to use these pages to monitor the contract's progress in responding to OMS.

For more information about the using the Summary Tracking and Case Tracking pages, see the Patient Safety Web Portal User Guide on the Help Documents page of the Patient Safety Analysis Web Portal.

### 5.1 Summary Tracking Page

The Summary Tracking page provides sponsors with an overview of the number of unique ORF cases requiring a response for a given report date, by contract. If a contract did not have any ORF cases requiring a response in the given reporting period, all fields are populated with zero.

### 5.2 Case Tracking Page

The Case Tracking page allows sponsors to view status information for ORF cases and the submitted responses. The Case Tracking Page includes three status fields that are described below:

- **Submission Status** – This status indicates whether a response was successfully 'Submitted' or 'Not Submitted' for the given case.
- **Review Status** – If the 'Submission Status' is 'Submitted', then the 'Review Status' is populated with the Review Status value from the submitted ORF. This value can be 'R1' or 'R2'. See Section 4.2 for more information regarding these response codes.
- **Validation Status** – This status indicates whether the response combination is deemed 'Valid' or 'Invalid'.

**Note:** Before the ORF is submitted, the three statuses fields default to "Not Submitted". Table 12 provides more information about the information displayed on the Case Tracking page.

Table 12. Case Tracking

Data Element	Element Description
Contract	CNNNN
Case Number	CNNNN NNNNNNN
Submission Status	Not Submitted / Submitted
Review Status	Not Submitted / R1 / R2
Validation Status	Not Submitted / Pending / Valid / Invalid
Date Reported	mm/dd/yyyy
Deadline	mm/dd/yyyy
Last Update	mm/dd/yyyy

## Appendix A: Average MME Calculation:

This appendix outlines the steps that are used to calculate the average MME for one beneficiary example. For the purposes of this appendix, the beneficiary example that is referenced throughout the remaining sections is assumed to have received three methadone claims and four non-methadone claims.

### A.1 Step 1: Calculate Dosage Units per Day and Daily Dose per Claim

First, the dosage units per day are calculated for both non-methadone and methadone claims. Dosage units per day is calculated by dividing quantity supplied by days supply. Second, the MME or daily dose per claim is calculated as the dosage units per day multiplied by the strength and MME CF, if applicable. For non-Methadone claims, the MME CF is used in the daily dose per claim calculation. Methadone claims use a graduated MME CF that is implemented in Step 2, thus the methadone MME CF is left out of the daily dose per claim calculation.

#### A.1.1 Non-Methadone Claims:

In the first row of Table 13, the quantity supplied is 10, the days supply is 2, the strength is 30, and the MME CF is 1. The dosage units per day and MME daily dose per claim for this row is calculated as follows:

Dosage units per day:  $(10/2) = 5$

MME daily dose per claim:  $(5 \times 30 \times 1) = 150$

Table 13: Non-Methadone Dosage Units per Day and Daily Dose per Claim Examples

Claim	Fill Date	Days Supply	Quantity Supplied	Strength	MME CF	Dosage Units per Day	MME Daily Dose (mg) per Claim
Morphine #1	01/01/2019	2	10	30	1	5	150
Morphine #2	01/03/2019	2	20	10	1	10	100
Morphine #3	01/03/2019	1	4	10	1	4	40
Morphine #4	01/06/2019	1	16	10	1	16	160

#### A.1.2 Methadone Claims:

In the first row of Table 14, the quantity supplied is 8, the days supply is 4, and the strength is 10. The dosage units per day and daily dose per claim for this row is calculated as follows:

Dosage units per day:  $(8/4) = 2$

Daily dose per claim:  $(2 \times 10) = 20$

Table 14: Methadone Dosage Units per Day and Daily Dose per Claim Examples

Claim	Fill Date	Days Supply	Quantity Supplied	Strength	Dosage Units per Day	Daily Dose (mg) per Claim
Methadone #1	01/01/2019	4	8	10	2	20
Methadone #2	01/04/2019	1	3	5	3	15
Methadone #3	01/06/2019	2	4	10	2	20

## A.2 Step 2: Calculate Daily MME

Next, the daily dose for both the methadone and non-methadone claims are assigned across each calendar day with utilization as described below:

- Start Day = Fill Date
- End Day = Fill Date + Days Supply - 1
- Utilization Days = Start Day to End Day

A total daily MME is then calculated by summing up the daily dose for all claims for each day in the measurement period. A graduated MME conversions factor is applied to calculate the total daily MME for methadone claims in this step.

### A.2.1 Daily Non-Methadone MME Calculation:

The Morphine #2 and Morphine #3 claims have one day of overlap. This means that the beneficiary filled their third Morphine prescription before their second Morphine claim's day supply ended. The Morphine #1 and Morphine #4 claims do not overlap with any other non-methadone prescriptions.

Table 15 assigns MME daily dose per claim (mg) across the usage days. The total daily MME is calculated by summing up the MME daily dose for all claims for each day in the measurement period.

Table 15: Daily MME for Non-Methadone Claims Examples

Claim	Metric	1/1/2019	1/2/2019	1/3/2019	1/4/2019	1/5/2019	1/6/2019	1/7/2019
Morphine #1	MME daily dose	150	150	-	-	-	-	-
Morphine #2	MME daily dose	-	-	100	100	-	-	-
Morphine #3	MME daily dose	-	-	40	-	-	-	-
Morphine #4	MME daily dose	-	-	-	-	-	160	-
<b>Non-Methadone</b>	<b>Total Daily MME</b>	<b>150</b>	<b>150</b>	<b>140</b>	<b>100</b>	<b>-</b>	<b>160</b>	<b>-</b>

In Table 15, rows 2 and 3 contain Morphine #2 and Morphine #3 prescriptions that have a 1 day overlap on 1/3/2019. The total Daily MME for 1/3/2019 is calculated by summing the MME daily dose for each claim (100+40=140).



## A.2.2 Daily Methadone MME Calculation:

The beneficiary also has two methadone claims that have 1 day of overlap. This means that the beneficiary filled the second methadone claim before the first methadone supply expired. The third claim does not overlap with the first two claims.

Table 15 assigns the daily dose per claim (mg) across the usage days. Rows 1 and 2 contain Methadone #1 and Methadone #2 claims that have a day of overlap on 1/4/2019. Similar to what is done for non-methadone claims in Table 14, the total daily dose is calculated by summing up the daily dose per claim (mg) for each day within the measurement period.

An additional step is used for methadone claims, in which the total daily MME is calculated by multiplying the total daily dose with the appropriate graduated methadone CF. The graduated methadone CF that is used is determined by the total daily dose. The graduated methadone CFs can be found in the OMS Medication List that is made available on the Help Documents page of the Patient Safety Analysis Web Portal.

For example, on 1/1/2019 in Table 16, a daily dose of 20 is associated with a graduated methadone CF of 4. As a result, the total daily MME for 1/1/2019 is:  $20 \times 4 = 80$ . On 1/4/2019, the methadone daily dose falls in the range that is associated with a CF of 8.

Table 16: Daily MME for Methadone Claims Examples

Claim	Metric	1/1/2019	1/2/2019	1/3/2019	1/4/2019	1/5/2019	1/6/2019	1/7/2019
Methadone #1	Daily Dose	20	20	20	20	-	-	-
Methadone #2	Daily Dose	-	-	-	15			-
Methadone #3	Daily Dose	-	-	-	-	-	20	20
<b>Methadone</b>	<b>Total Daily Dose</b>	<b>20</b>	<b>20</b>	<b>20</b>	<b>35</b>	<b>-</b>	<b>20</b>	<b>20</b>
<b>Methadone</b>	<b>Total Daily MME</b>	<b><math>20 \times 4 = 80</math></b>	<b><math>20 \times 4 = 80</math></b>	<b><math>20 \times 4 = 80</math></b>	<b><math>35 \times 8 = 280</math></b>	<b>-</b>	<b><math>20 \times 4 = 80</math></b>	<b><math>20 \times 4 = 80</math></b>

## A.2.3 Daily MME Calculation:

Finally, the daily MME for both methadone and non-methadone claims for each day in the measurement period is summed to calculate the total daily MME. Table 17 calculates the total daily MME for each day by summing up the methadone and non-methadone rows.

Table 17: Total Daily MME Examples

Claim	Metric	1/1/2019	1/2/2019	1/3/2019	1/4/2019	1/5/2019	1/6/2019	1/7/2019
Methadone	Total Daily MME	80	80	80	280	-	80	80
Non-Methadone	Total Daily MME	150	150	140	100	-	160	-
<b>All</b>	<b>Total Daily MME</b>	<b>230</b>	<b>230</b>	<b>220</b>	<b>380</b>	<b>0</b>	<b>240</b>	<b>80</b>

### A.3 Step 3: Calculate Average MME

After calculating the total daily MME for the beneficiary on each day of the measurement period, the average MME is calculated by totaling the MME dispensed within the measurement period and dividing it by the duration of opioid usage. The duration of opioid usage is calculated by counting the number of days from the first and last day of opioid usage, including the first and last days. Despite not having any opioid utilization on 1/5/2019, this day is still included in duration of opioid usage.

The average MME calculation for the example beneficiary is as follows:

Total MME:  $(230 + 230 + 220 + 380 + 0 + 240 + 80) = \mathbf{1,380}$

Duration of Opioid Usage: **7**

Average MME:  $(1,300/7) = \mathbf{197.14}$

## Appendix B: Pharmacy Grouping Methodology

When a pharmacy has multiple locations that share real-time electronic data, all locations of the pharmacy must be counted as one pharmacy under the OMS criteria. CMS maps the National Provider Identifier (NPI) or National Council for Prescription Drug Programs (NCPDP) pharmacy ID to the NCPDP data file. The number of pharmacies is determined using the minimum number of groupings among chain pharmacies identified between the number of unique Federal Tax Identification Numbers (TIN), chain pharmacy names, and pharmacy 'Doing Business As' (DBA) names (i.e., name with store numbers removed) and adding this value to the number of unique TINs among franchise and individual pharmacies. An example of this pharmacy grouping methodology as it applies to a beneficiary who receives multiple opioid prescriptions is shown in Table 18 below.

Table 18: Pharmacy Information

Pharmacy ID/NPI	TIN	Chain Name <sup>7</sup>	DBA Name	Cleaned DBA Name	Pharmacy Type
111111111	111111111	n/a	TBD Pharmacy	TBD Pharmacy	Individual Pharmacy
211111112	123456789	ABCD Pharmacy INC,	ABCD Pharmacy #1234	ABCD Pharmacy	Chain
311111113	123456789	ABCD Pharmacy INC,	ABCD Pharmacy #1345	ABCD Pharmacy	Chain
411111114	222222222	XYZ Pharmacy INC	XYZ Pharmacy #1001	XYZ Pharmacy	Chain
511111115	333333333	n/a	PQRS Pharmacy at Lake DR	PQRS Pharmacy at Lake DR	Individual Pharmacy
611111116	333333333	n/a	PQRS Pharmacy at River DR	PQRS Pharmacy at River DR	Individual Pharmacy
711111117	987654321	LMNOP Pharmacy INC	LMNOP Pharmacy #011	LMNOP Pharmacy	Chain
811111118	999654321	LMNOP Pharmacy INC	LMNOP Pharmacy #012	LMNOP Pharmacy	Chain

In the Table 18 example above, the beneficiary received 8 opioid prescriptions during the 6-month measurement period. Each prescription was associated with a different pharmacy NPI, which matched the fictitious NCPDP information reported in the table. To count the number of pharmacies in this example, the following steps are followed:

**Step 1a: Calculate the unique number of TINs among chain pharmacies.** In the Table 18 example, there are 4 unique TINs among the chain pharmacies: 123456789, 222222222, 987654321, and 999654321.

**Step 1b: Calculate the unique number of chain names among chain pharmacies.** In the Table 18 example, there are 3 unique chain names among chain pharmacies: ABCD Pharmacy INC, XYZ Pharmacy INC, and LMNOP Pharmacy INC.

---

<sup>7</sup> Chain and Franchise names are only used for grouping if the relationship ID found in the NCPDP data associated with the pharmacy TIN has a relationship type of 'Chain' or 'Franchise.'

Step 1c: *Calculate the unique number of cleaned DBA names among chain pharmacies.* In the Table 18 example, there are 3 unique cleaned (i.e., store numbers removed) DBA names among chain pharmacies: ABCD Pharmacy, XYZ Pharmacy, and LMNOP Pharmacy.

Step 1d: *Determine the Chain pharmacy count.* The Chain pharmacy count is the minimum between calculated value in Steps 1a-1c. In the Table 18 example, the minimum value is derived from either Step 1b or 1c, 3 unique Chain names and 3 unique cleaned DBA names, respectively.

After the Chain pharmacy count is determined, the unique number of TINs for Franchise and Individual pharmacies are counted and added to the total pharmacy count:

Step 2. *Calculate the unique number of TINs among individual/franchise pharmacies.* In the Table 18 example, there are 2 unique TINs among the individual/franchise pharmacies: 111111111 and 333333333.

Once the Franchise and Individual pharmacies are counted, the totals from Step 1d and Step 2 are added together for the final pharmacy count:

Step 3. *Determine the total pharmacy count.* This final calculation is the sum of the chain pharmacy count (Step 1d) and the unique number of TINs among individual/franchise pharmacies (Step 2). In the Table 18 example, the resulting sum is 3 (Step 1d) + 2 (Step 2) = 5

In summation, this example beneficiary received opioids from five pharmacies using the OMS pharmacy grouping methodology, and hence meets the minimum OMS criteria pharmacy count requirement.

## Appendix C: Prescriber Grouping Methodology

To count prescribers in the OMS, individual prescribers are grouped when a relationship between individual opioid prescribers and organizations can be established. Individual prescribers who share the same organizational Tax Identification Number (TIN) are grouped and counted as one prescriber.

Table 19: Prescriber Grouping Example 1

Prescriber NPI	Organization TIN	Group/Individual Determination
111111111	123456789	Prescriber Group 1
111111112	123456789	Prescriber Group 1
111111113	123456789	Prescriber Group 1
111111114	523456799	Individual Prescriber 2
111111115	993456788	Individual Prescriber 3

In Table 19, the individual prescriber NPI and Organization TIN associated with each opioid prescriber is provided. Assume the beneficiary meets the MME criterion and received opioid prescriptions from 3 prescribers in the same group practice and 2 independent opioid prescribers (1 group practice + 2 individual prescribers = 3 total prescribers) and filled the prescriptions at 4 opioid dispensing pharmacies that do not share real-time electronic data. In this example, the beneficiary has 3 total prescribers after grouping and meets the other qualifying criteria. Thus, the beneficiary meets the minimum OMS criteria.

Table 20: Prescriber Grouping Example 2

Prescriber NPI	Organization Tax Identification Number	Group/Individual Determination
222222222	123498765	Prescriber Group 1
222222223	223456789	Individual Prescriber 2
222222224	123498765	Prescriber Group 1
222222225	123498765	Prescriber Group 1

In Table 20, assume that the beneficiary meets the MME criterion and received opioid prescriptions from 3 prescribers in the same group practice and 1 independent opioid prescriber (1 group practice + 1 individual prescriber = 2 prescribers) and filled the prescriptions at 4 opioid dispensing pharmacies that do not share real-time electronic data. In this example, the beneficiary does not meet the minimum OMS criteria as they have only two prescribers after grouping.